About MediSieve
MediSieve is a company based in London (United Kingdom) founded in 2014 by George Frodsham. MediSieve has raised $4.18 million across 5 funding rounds from investors including UK Research and Innovation, European Union and 24 Haymarket. The company has 12 employees. MediSieve offers products and services including MediSieve System, AAV Gene Therapy Enabler, IL-6 Driven Hyperinflammation Treatment, and Severe Malaria Treatment. MediSieve operates in a competitive market with competitors including Haemonetics, Vetex Medical, Immutrix Therapeutics, Hemostasis and Immunocept Medical Products, among others.
- Headquarter London, United Kingdom
- Employees 12
- Founders George Frodsham
- SectorsHealthcare
- Email••••••••
- Website medisieve.com
- Social LinkedIn X
- Legal Name Medisieve Ltd
- Date of Incorporation 08 Apr, 2014
- Jurisdiction LONDON, ENGLAND
- Total Equity Funding$4.18M (USD)
in 5 rounds
- Latest Funding Round$2.14M (USD), Series A
Jun 2021
- InvestorsUK Research and Innovation
& 3 more
- Employee Count12
Products & Services of MediSieve
MediSieve offers a comprehensive portfolio of products and services, including MediSieve System, AAV Gene Therapy Enabler, IL-6 Driven Hyperinflammation Treatment, and Severe Malaria Treatment.
Purifies blood by removing pathogens with magnetic beads.
Depletes antibodies to facilitate novel gene therapies.
Treats hyperinflammation by depleting specific cytokines.
Removes infected cells to manage severe malaria cases.
Funding Insights of MediSieve
MediSieve has successfully raised a total of $4.18M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $2.14 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.18M
- Total Rounds 5
- Last Round Series A — $2.14M
- First Round $52,630
(Jan 2017)
- Investors Count 4
All 5 funding rounds of MediSieve with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $2.14M | Series A | – | 24 Haymarket | – |
| Jun 2021 | $2.23M | Grant | – | – | |
| Jun 2018 | $2.04M | Seed | – | 24 Haymarket | – |
| Jun 2017 | $57,046 | Grant | – | – | |
| Jan 2017 | $52,630 | Grant | – | – |
4 investors in total: 4 institutional.
Investors in MediSieve
MediSieve has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include UK Research and Innovation, European Union and 24 Haymarket.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tech focused VC firm investing in the UK | – | 24haymarket.com | London, United Kingdom | |
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Research and innovation funding is managed for UK advancement. | 2018 | ukri.org | Swindon, United Kingdom | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for MediSieve
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MediSieve
5 people are tracked at MediSieve (3 in leadership, 2 in team); the tracked headcount is 12.
| Name | Role | Group |
|---|---|---|
George Frodsham | Founder & CEO | Leadership |
Cristina Blanco-Andujar | Chief Technology Officer | Leadership |
William Twigger | Head of Engineering and Quality | Leadership |
Elinor Jones | Regulatory Affairs Manager | Team |
Neil Barker | Quality Manager | Team |
Complete people profiles for MediSieve
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of MediSieve
3 dated milestones of MediSieve across 7 years, from founding to its latest funding, stage changes and deals.
- Founded MediSieve is founded.
- Funding First funding round of $53K.
- Funding Latest funding round, Series A, of $2.1M.
Competitors of MediSieve
MediSieve operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Haemonetics, Vetex Medical, Immutrix Therapeutics, Hemostasis and Immunocept Medical Products, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| haemonetics.com | 1971 | Braintree, United States | – | 3,034 | Hematology products and solutions are provided for medical applications. | |
| vetexmedical.com | 2016 | Galway, Ireland | – | – | Catheters for venous clot management and removal are developed. | |
| immutrix.com | 2009 | Rapid, United States | $14.02M | – | Blood cleansing treatment device | |
| hemostasisllc.com | 2006 | Saint Paul, United States | – | – | Develops and manufactures hemostatic products for surgical bleeding control and patient care. | |
| immunocept.com | 1999 | Denver, United States | $530,000 | – | Blood filtration therapy for severe sepsis is developed. | |
| straubmedical.com | 1997 | Vilters Wangs, Switzerland | – | – | Medical devices for treating peripheral vascular diseases are developed. | |
| fiveliters.com | 2022 | Dallas, United States | $500,000 | – | Developer of medical device for non-invasive neuromodulation of hemorrhaging | |
| exvivodynamics.com | 2013 | New York, United States | – | – | Microparticles are filtered from stored blood for transfusion safety. |
Detailed competitors of MediSieve
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Medisieve
Complete news archive for MediSieve
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to MediSieve
10 companies that operate in the same segment as MediSieve (Hematology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small activating RNA therapeutics are developed to restore gene function. | 2008 | London, England, United Kingdom | USD 460.41 M | USD 23.07 M | 37 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 442 M | – | 66 | |
Developer of therapeutics for the treatment of hematologic diseases | 2017 | Cambridge, Massachusetts, United States | USD 140 M | – | 84 | |
Gene therapy platform is developed for chronic disease treatments. | 2015 | Stevenage, Hertfordshire, United Kingdom | USD 273.69 M | USD 435.87 K | 152 | |
Novel anticoagulants for thrombosis treatment are developed. | 2019 | Cambridge, Massachusetts, United States | USD 250 M | – | 14 | |
Developer of therapies for treating hemochromatosis & beta thalassemia | 1989 | San Diego, California, United States | – | USD 75.72 M | 71 | |
Breakthrough therapies are developed for blood diseases and infections. | 2014 | Buffalo, New York, United States | USD 1 M | – | 22 | |
Hematology products and solutions are provided for medical applications. | 1971 | Braintree, Massachusetts, United States | – | USD 1.33 B | 3,020 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about MediSieve
MediSieve was founded in 2014 and raised its 1st funding round 3 years after it was founded.
MediSieve is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
George Frodsham is the current CEO of MediSieve. They have also founded this company.
MediSieve is a funded company, having raised a total of $4.18M across 5 funding rounds to date. The company's 1st funding round was a Grant of $52.63K, raised on Jan 2017.
MediSieve has 12 employees.
MediSieve was founded in 2014 in London, United Kingdom, and operates in the biotechnology sector. Magnetic blood filtration solutions are developed by the company to remove infected cells, pathogens, toxins, and viruses from blood. The Medisieve device integrates peristaltic haemofiltration pumps with antibody-coated magnetic particles, targeting specific cells or antigens for treating blood-borne diseases. Operations focus on therapeutic applications in healthcare.
MediSieve's top competitors include Haemonetics, Vetex Medical and Immutrix Therapeutics.
MediSieve offers MediSieve System, AAV Gene Therapy Enabler, IL-6 Driven Hyperinflammation Treatment, and Severe Malaria Treatment.
MediSieve has 4 investors. Key investors include UK Research and Innovation, European Union, 24 Haymarket, and EIC Fund.
MediSieve operates through Medisieve Ltd.